Portuguese 
English 
Spanish 
2 min of reading 
0 comments 
Mass Layoffs Expose Fragility of Danish Giant Amid Weight Loss Drug War
The leadership of Novo Nordisk, manufacturer of the weight loss medication Wegovy, announced on Wednesday (10) that it will lay off 9,000 people.
The layoffs are part of the company’s attempt to regain growth and defend itself against competition from the American Eli Lilly, as well as the pressure from generic drugs that are beginning to advance in the market.
According to the company, the restructuring is expected to generate savings of 8 billion Danish crowns (US$ 1.25 billion) per year, at a time when Novo Nordisk is facing a slowdown in its key obesity and diabetes medications.
-
The United States purchased for $125 million a ship that Shell used for drilling oil in the Arctic, spent another $25 million refurbishing it, and renamed it Storis because the largest economy on the planet can no longer build an icebreaker on its own.
-
The largest highway concession company in Brazil already belongs to an Italian group, and now the railway sector may be next to receive billions in investments from Italy amid the progress of the Mercosur and European Union agreement.
-
Work less and earn the same? PEC discussed by Lula and Hugo Motta affects the 6×1 schedule and reignites the debate on working hours, days off, and salary in Brazil.
-
Companies from Ceará generate billions and dominate Brazil without many people noticing, with giants born in the state such as Hapvida, Pague Menos, M. Dias Branco, and Três Corações totaling almost R$ 104 billion in revenue just in 2024.
From Global Champion with Wegovy to Billion-Dollar Loss: How Novo Nordisk’s Rise Turned into Free Fall
The company also issued its third profit warning of the year, citing 9 billion crowns in non-recurring costs related to the restructuring.
Nova Nordisk’s meteoric rise began in mid-2021, when Wegovy was approved in the United States as the first effective drug for obesity, catapulting the company to the top of the European stock market.
However, the wave of hiring that nearly doubled its workforce in five years has become a problem. Now, the cuts represent an attempt to “return to reality.”
Analyst Simon Baker from Redburn Atlantic was straightforward: “The mass layoffs bring Novo’s employee count back to levels seen at the beginning of 2024.”
Competition from Eli Lilly, Pressure from Generics and Billion-Dollar Cuts: Challenges That Could Define Novo Nordisk’s Future
The crisis did not stop with the cuts. In July, investors withdrew US$ 70 billion from the pharmaceutical company’s market value following a new profit alert and the appointment of veteran Mike Doustdar as CEO.
Since the beginning of the year, Novo Nordisk’s shares have already fallen nearly 46%, reducing its market capitalization to around US$ 181 billion — well below the peak of US$ 650 billion recorded last year.
In practice, this means that the company has lost approximately US$ 470 billion in market value in just over a year, a drop that has called into question its global leadership position.
The case of Novo Nordisk shows how success can turn into a crisis in just a few years. A company that once led the European market now faces tough cuts and increasingly impatient investors.
And you, do you believe that Novo Nordisk still has the stamina to reinvent itself with Wegovy, or will competitor Eli Lilly completely take the lead in this billion-dollar market?
-
-
4 people reacted to this.